key: cord-0718473-aer5uyo7 authors: Grote, Ludger; McNicholas, Walter T.; Hedner, Jan title: Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA) date: 2020-05-04 journal: Eur Respir J DOI: 10.1183/13993003.01323-2020 sha: 025d2c609de60ac8cf3202b088ecc3c16f86b3c6 doc_id: 718473 cord_uid: aer5uyo7 Sleep disordered breathing (SDB) is highly prevalent with a male to female predominance of two to one, and is more common in middle-aged and elderly subjects [1]. Affected patients often present with comorbidities such as obesity, cardiovascular disease (systemic hypertension, heart failure, atrial fibrillation), and diabetes mellitus Type II [2]. The strong overlap between the profile for SDB patients and the identified risk factors for adverse outcomes of COVID-19 infection that include age, male gender, and cardio-metabolic comorbidity [3] suggest that SDB patients may benefit from effective therapy if confronted with COVID-19 infection [4]. Sleep disordered breathing (SDB) is highly prevalent with a male to female predominance of two to one, and is more common in middle-aged and elderly subjects (1) . Affected patients often present with comorbidities such as obesity, cardiovascular disease (systemic hypertension, heart failure, atrial fibrillation), and diabetes mellitus Type II (2) . The strong overlap between the profile for SDB patients and the identified risk factors for adverse outcomes of COVID-19 infection that include age, male gender, and cardio-metabolic comorbidity (3) suggest that SDB patients may benefit from effective therapy if confronted with COVID-19 infection (4). The COVID-19 pandemic has fundamentally changed the operation of health care systems around the globe. Resources have understandably been shifted from elective care to acute management of severely ill patients with life-threatening COVID-19 infection (5) . According to current recommendations, sleep medicine services are advised to reduce in-house services, and to provide medical care by remote contact using phone, video-calls, and telemedicine solutions (6, 7, 8, 9) . In the current study, we assessed the impact of the COVID-19 pandemic on the management of SDB patients in Europe. We approached the centres of the European Sleep Apnoea Database (ESADA) cohort, a well-established network of sleep centres in 19 European countries (2) , and a subsample of accredited sleep centres of the German Sleep Society (DGSM). The aim was to analyse how recommendations from expert organisations were applied across various European regions, and whether specific mitigation strategies were already in practice. A purpose-built questionnaire addressed information about changes in clinical routines imposed during the COVID-19 pandemic compared with routine practices. Specifically, details on the diagnosis of SDB, the procedures for titration of positive airway pressure (PAP) treatment, and the follow up of PAP treatment were addressed. One question sought the estimated proportion of staff still active in the sleep service during the pandemic compared with beforehand (0-100%, each for "physicians" and "nurses/technicians"). Finally, access to regional or national COVID-19 related guidelines for patients with SDB and for caregivers in sleep medicine services was evaluated. Actual numbers of confirmed Diagnostic routines were changed substantially by the pandemic. Prior to the pandemic, laboratory-based polysomnography was performed "rarely or regularly" in 92.5% of centres but only in 20% during the pandemic (p<0.001, table). On the other hand, telemedicinebased sleep apnoea diagnosis was used in 30.0% of centres prior to the pandemic and this number was only marginally reduced to 27.5% during the pandemic. From the 10 centres regularly using telemedicine-based diagnosis, three stopped the service during the pandemic, four maintained the level of use, and three increased use from rarely to regularly. Only two centres started this routine during the pandemic. Prior to the pandemic, laboratory-based CPAP or bi-level PAP titration and initiation were practiced in almost all centres but less than one fifth of centres continued this routine during the pandemic (p<0.001, table). In the 13 centres already practicing telemedicinebased CPAP titration, four stopped the service, one reduced the use, six maintained the level of use, and two increased the use from rarely to regularly. Four centres started this routine during the pandemic. Prior to the pandemic, 39 centres report regular follow-up procedures in patients with SDB. This service continued in 36 centres during the pandemic but the mode of follow up had changed (table 1) between an imbalance of the Angiotensin II receptor and Angiotensin II Converting Enzyme (ACE2) and severe COVID-19 infections, which may also apply in SDB (11, 12) . In conclusion, our findings suggest that the sleep medicine community needs to collaborate in developing strategies for care of patients with both suspected and established SDB during major events such as the COVID-19 pandemic. Activities need to focus on the recognition of severe cases of SDB and how to initiate treatment in already identified severe cases. The potential of new technologies that enable remote monitoring to optimize treatment may be more frequently applied during times of restricted health care resources in order to obtain better management of severely affected COVID-19 patients. In lab titration -87.5% Ambulatory titration -40.0% Telemedicine based BiLevel-PAP titration -20.0% (Regularly 4 centres) In lab titration -17.5% Ambulatory titration -17.5% Telemedicine based BiLevel-PAP titration 12.5% (Regularly 3 centres) In lab follow up -82.5% Ambulatory titration -Distance follow up: Base on phone calls: 70% Based on telemonitoring -50.0% ("Regularly use" at 7 centers) In lab Follow up -7.5% Ambulatory titration -17.5% (all rarely) Distance follow up: Base on phone calls: 75.0% Based on telemonitoring -57.5% ("Regularly use at 12 centers, 8 centers started, 4 centers stopped telemonitoring for PAP follow up) Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Case for continuing community NIV and CPAP during the COVID-19 epidemicThorax Epub ahead of print Swedish perioperative registry SPOR (www.spor.se): Publication at Swedish Broadcast SVT, downloaded British Thoracic Society: Advice for those seeing patients with obstructive sleep apnoea American Academy Sleep Medicine: COVID-19 mitigation strategies for sleep clinics and labs. Updated document at A: GAVO2 procedures (French scientific group on chronic ventilation and oxygen) TITLE: Homecare respiratory equipment for patients suspected to be infected with the respiratory virus Covid19 (English version) Vägledning angående coronavirus (COVID-19) och obstruktiv sömnapné (OSA) Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation Sympathoexcitation and arterial hypertension associated with obstructive sleep apnea and cyclic intermittent hypoxia Istituto per la Ricerca e l'Innovazione Biomedica Service d'Explorations Fonctionnelles Multidisciplinaires, and Unité de Médecine du Sommeil Sleep Medicine, Sahlgrenska University Hospital and Sahlgrenska Academy Sleep Disorders Centre, Department of Cardiovascular Neural and Metabolic Sciences Respiratory Failure Unit, G. Papanikolau Hospital Sleep Unit Pulmonary Medicine Sleep Disorders Centre Sleep Disorders Centre, University Hospital Gasthuisberg Accredited sleep centres of the German Sleep Society (DGSM) participating in the study